Frailty is a clinical syndrome of increased vulnerability to adverse health outcomes following a stressor event — such as acute illness, hospitalisation, surgery or medication change — resulting from age-related cumulative decline across multiple physiological systems. A frail person has reduced physiological reserves and limited ability to compensate for additional stressors. The Fried phenotype defines frailty as ≥3 of 5 criteria: unintentional weight loss; exhaustion; weakness (grip strength); slowness (gait speed); low physical activity. Approximately 10-15% of community-dwelling adults over 65 are frail; approximately 40-50% are "pre-frail" (1-2 criteria). Frailty is not an inevitable consequence of ageing — it can be prevented, slowed and sometimes reversed.

What is sarcopenia and how is it diagnosed?

Sarcopenia is the age-related loss of skeletal muscle mass, strength and function — defined and diagnosed by EWGSOP2 (2018) criteria: Probable sarcopenia: low muscle strength — grip strength 15 seconds. Confirmed sarcopenia: low muscle strength PLUS low muscle mass — measured by DXA (the gold standard: appendicular skeletal muscle mass index <7.0 kg/m² men, <5.5 kg/m² women), BIA or CT. Severe sarcopenia: low strength + low mass + low physical performance (gait speed ≤0.8 m/s or SPPB ≤8). Grip strength dynamometry is cheap, quick and reproducible — a practical clinical tool.

How is frailty treated?

No pharmacological treatment is approved for frailty or sarcopenia. Evidence-based interventions: (1) Resistance exercise (the most effective single intervention): progressive resistance training 2-3 times per week — improves muscle mass, strength, gait speed and balance even in 80-90-year-olds; reduces falls; reduces hospitalisation. (2) Protein intake: increase to 1.2-1.6g/kg/day (leucine-rich sources — whey protein, dairy, eggs, meat, legumes); supplement meals with protein (resistance training + protein = synergistic). (3) Vitamin D: correction reduces falls risk in deficient older adults (800 IU/day — routine in most frail older adults). (4) Comprehensive geriatric assessment (CGA): identifies and treats reversible contributors (anaemia, hypothyroidism, depression, medication adverse effects, malnutrition, social isolation). (5) Multidisciplinary intervention: combining exercise + nutrition + cognitive stimulation + social engagement.

What is the Clinical Frailty Scale?

The Clinical Frailty Scale (CFS) is a validated 9-point scale developed by Kenneth Rockwood for rapid bedside frailty assessment: 1 Very Fit; 2 Well; 3 Managing Well; 4 Living with Very Mild Frailty; 5 Living with Mild Frailty; 6 Living with Moderate Frailty; 7 Living with Severe Frailty; 8 Living with Very Severe Frailty; 9 Terminally Ill. Based on a brief clinician assessment of activity, independence and medical complexity — takes <5 minutes. During COVID-19, CFS was used widely for ICU triage and consistently predicted 30-day mortality better than chronological age: patients with CFS ≥6 had dramatically higher mortality, driving difficult but evidence-based resource allocation decisions.

Can frailty be reversed?

Pre-frailty (1-2 Fried criteria) can frequently be reversed — this is the critical intervention window. Intensive multicomponent interventions (resistance + aerobic exercise + balance training + protein supplementation + vitamin D) can improve frail older adults to pre-frail and sometimes robust status over 12-24 weeks. The LIFE study (NEJM 2014): structured physical activity vs health education in 1,635 sedentary older adults — 18% reduction in major mobility disability. The FRAIL-STOP trial and multiple systematic reviews confirm reversal is possible in pre-frailty and mild frailty. Reversal from moderate-severe frailty is less common but functional improvements remain achievable. The message: frailty is not an irreversible final state — it is a syndrome with evidence-based interventions.

How does GMJ News cover frailty and sarcopenia?

GMJ News covers the Clinical Frailty Scale (CFS) and COVID triage, Fried phenotype, EWGSOP2 sarcopenia criteria (strength > mass), grip strength assessment, protein 1.2-1.6g/kg European consensus, resistance exercise as the primary intervention, SPPB assessment, polypharmacy and deprescribing (STOPP/START), comprehensive geriatric assessment, falls prevention, pre-frailty as the intervention window, and the distinction from normal ageing. Frailty and sarcopenia are directly relevant to PHIG's ageing population programme, hospital accreditation (CGA as quality indicator), and Georgia's rapidly ageing demographic.

Home › Topics › Frailty and Sarcopenia

Frailty and Sarcopenia

Q: How is frailty treated?

No pharmacological treatment is approved for frailty or sarcopenia. Evidence-based interventions: (1) Resistance exercise (the most effective single intervention): progressive resistance training 2-3 times per week — improves muscle mass, strength, gait speed and balance even in 80-90-year-olds; reduces falls; reduces hospitalisation. (2) Protein intake: increase to 1.2-1.6g/kg/day (leucine-rich sources — whey protein, dairy, eggs, meat, legumes); supplement meals with protein (resistance training + protein = synergistic). (3) Vitamin D: correction reduces falls risk in deficient older adults (800 IU/day — routine in most frail older adults). (4) Comprehensive geriatric assessment (CGA): identifies and treats reversible contributors (anaemia, hypothyroidism, depression, medication adverse effects, malnutrition, social isolation). (5) Multidisciplinary intervention: combining exercise + nutrition + cognitive stimulation + social engagement.

Q: What is the Clinical Frailty Scale?

The Clinical Frailty Scale (CFS) is a validated 9-point scale developed by Kenneth Rockwood for rapid bedside frailty assessment: 1 Very Fit; 2 Well; 3 Managing Well; 4 Living with Very Mild Frailty; 5 Living with Mild Frailty; 6 Living with Moderate Frailty; 7 Living with Severe Frailty; 8 Living with Very Severe Frailty; 9 Terminally Ill. Based on a brief clinician assessment of activity, independence and medical complexity — takes <5 minutes. During COVID-19, CFS was used widely for ICU triage and consistently predicted 30-day mortality better than chronological age: patients with CFS ≥6 had dramatically higher mortality, driving difficult but evidence-based resource allocation decisions.

Q: Can frailty be reversed?

Pre-frailty (1-2 Fried criteria) can frequently be reversed — this is the critical intervention window. Intensive multicomponent interventions (resistance + aerobic exercise + balance training + protein supplementation + vitamin D) can improve frail older adults to pre-frail and sometimes robust status over 12-24 weeks. The LIFE study (NEJM 2014): structured physical activity vs health education in 1,635 sedentary older adults — 18% reduction in major mobility disability. The FRAIL-STOP trial and multiple systematic reviews confirm reversal is possible in pre-frailty and mild frailty. Reversal from moderate-severe frailty is less common but functional improvements remain achievable. The message: frailty is not an irreversible final state — it is a syndrome with evidence-based interventions.

Q: How does GMJ News cover frailty and sarcopenia?

GMJ News covers the Clinical Frailty Scale (CFS) and COVID triage, Fried phenotype, EWGSOP2 sarcopenia criteria (strength > mass), grip strength assessment, protein 1.2-1.6g/kg European consensus, resistance exercise as the primary intervention, SPPB assessment, polypharmacy and deprescribing (STOPP/START), comprehensive geriatric assessment, falls prevention, pre-frailty as the intervention window, and the distinction from normal ageing. Frailty and sarcopenia are directly relevant to PHIG's ageing population programme, hospital accreditation (CGA as quality indicator), and Georgia's rapidly ageing demographic.

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Frailty — a state of increased physiological vulnerability to adverse outcomes after a stressor event, resulting from cumulative decline across multiple biological systems — and sarcopenia — the age-related loss of skeletal muscle mass, strength and function — are two closely related but distinct geriatric syndromes affecting approximately 10-15% of community-dwelling adults over 65 and 25-50% of hospitalised patients over 65, independently predicting falls, hospitalisation, disability and death, yet remaining systematically under-recognised and under-addressed in clinical care despite having effective interventions available (WHO). Resistance exercise is the single most evidence-based intervention for both sarcopenia and frailty — improving muscle mass, strength, physical function and reducing fall risk regardless of age — while adequate protein intake (≥1.2-1.6g/kg/day in older adults, per European consensus) is the essential nutritional partner, and the Clinical Frailty Scale (Rockwood, 9-point) provides a rapid validated clinical assessment tool proven to predict outcomes better than chronological age alone.

Key messages

Clinical Frailty Scale — 9-point rapid assessment predicting outcomes better than age

The Clinical Frailty Scale (CFS, Rockwood) — a 9-point scale from Very Fit (1) to Terminally Ill (9) — is the most widely used clinical frailty assessment tool globally. It was used extensively during COVID-19 pandemic triage and consistently predicted 30-day mortality better than chronological age alone. CFS ≥6 (Moderately to Severely Frail) identifies patients at dramatically higher risk of adverse outcomes after acute illness.

Resistance exercise — the single most evidence-based intervention

Progressive resistance exercise training (strength training) has the strongest evidence for improving muscle mass, strength and physical function in both sarcopenia and frailty — regardless of age. Even 80-90-year-old frail individuals respond to structured resistance exercise. Meta-analyses confirm significant improvements in gait speed, grip strength, chair stand performance, balance and falls risk with resistance training programmes of 8-24 weeks.

Protein — 1.2-1.6g/kg/day in older adults (not 0.8g WHO RDA)

The WHO recommended daily allowance for protein (0.8g/kg/day) is based on nitrogen balance studies in young adults and is insufficient to prevent or treat sarcopenia in older people. European consensus (PROT-AGE, ESCEO/EUGMS): older adults should consume 1.2-1.6g protein/kg body weight per day to maintain muscle mass. Higher protein requirements apply in illness/hospitalisation. Leucine-rich sources (whey, dairy, meat, eggs, legumes) are most anabolic due to leucine's mTORC1 signalling effect.

EWGSOP2 — the European sarcopenia diagnostic criteria

The European Working Group on Sarcopenia in Older People (EWGSOP2, 2018) criteria: (1) Probable sarcopenia: low muscle strength (grip strength <27kg men / <16kg women OR 5-times chair stand >15 seconds). (2) Confirmed sarcopenia: low muscle mass (DXA, BIA, CT) in addition to low strength. (3) Severe sarcopenia: low physical performance (gait speed ≤0.8m/s OR SPPB ≤8) in addition. Muscle strength — not muscle mass — is the primary diagnostic criterion in EWGSOP2.

Comprehensive geriatric assessment — the gold standard for frail patients

Comprehensive geriatric assessment (CGA) — a multidisciplinary evaluation of an older person's medical, functional, cognitive, psychological and social needs — is the gold standard clinical process for frail patients. CGA guides: individualised care planning; medication review and deprescribing; falls prevention; rehabilitation goals; care home vs home-based care decisions; end-of-life planning. RCTs confirm CGA reduces mortality, institutionalisation and functional decline compared to standard care in hospitalised frail older adults.

Pre-frailty is reversible — the intervention window

Fried's phenotype: pre-frailty (1-2 criteria) affects approximately 40-50% of adults over 65 — a critical intervention opportunity. Pre-frailty can progress to frailty or reverse to robustness. Effective interventions in pre-frailty: combined exercise (resistance + aerobic + balance); protein supplementation + resistance training; vitamin D correction; social engagement; medication review (polypharmacy as a frailty driver). Reversal from frailty to pre-frailty (or robustness) is possible with targeted intervention — but less common than prevention.

Key statistics

10-15%

community-dwelling adults over 65 meet frailty criteria

Fried et al./WHO

25-50%

of hospitalised patients over 65 are frail

WHO/Geriatrics

9-point CFS

Clinical Frailty Scale (Rockwood) — rapid frailty assessment, better predictor than age

Rockwood 2005

1.2-1.6g/kg

protein/day — European consensus for older adults (vs 0.8g WHO RDA)

PROT-AGE/ESCEO

EWGSOP2 2018

updated European sarcopenia criteria: strength → mass → performance (in that order)

Cruz-Jentoft 2019

Resistance exercise

strongest evidence for sarcopenia/frailty reversal regardless of age

Cochrane/Meta-analysis

Clinical Frailty Scale — 9-point categories and clinical outcomes

Source: Rockwood et al. CFS ≥5 associated with dramatically increased adverse outcomes; CFS ≥7 = very severe frailty.

Glossary of key terms

Fried frailty phenotype
Cardiovascular Health Study 2001Linda Fried et al. (2001) defined frailty as a clinical syndrome with ≥3 of 5 criteria: (1) Unintentional weight loss (>4.5kg or >5% body weight in the past year); (2) Exhaustion (self-reported — two CES-D questionnaire items); (3) Weakness (grip strength below the lowest 20th percentile by sex and BMI); (4) Slowness (walking 15 feet in the slowest 20th percentile by sex and height); (5) Low physical activity (<383 kcal/week men; <270 kcal/week women). Pre-frailty: 1-2 criteria. Frailty: ≥3 criteria. The most widely validated phenotype model.

Sarcopenia vs frailty distinction
EWGSOP2/WHOSarcopenia and frailty overlap but are distinct: Sarcopenia: primarily a muscle condition — defined by low muscle mass + strength/performance. Can occur in normal-weight individuals and at younger ages in some conditions (cancer, inflammatory disease). Frailty: a broader multisystem vulnerability state — includes physical (sarcopenia component), cognitive, psychological and social dimensions. A person can be sarcopenic without being frail (compensated by other factors); frailty always includes some sarcopenic component. Interventions targeting both: resistance exercise is central to both.

Muscle strength vs muscle mass
EWGSOP2 2018A paradigm shift in sarcopenia diagnosis: EWGSOP2 (2018) placed muscle strength as the primary diagnostic criterion — overturning the earlier emphasis on muscle mass. This reflects the finding that muscle strength (particularly grip strength and chair stand performance) is a better predictor of adverse outcomes (falls, hospitalisation, mortality) than muscle mass alone. Muscle quality (force per unit mass) declines with age due to: neural changes (motor unit remodelling, reduced motor neurone firing); intramuscular fat infiltration; mitochondrial dysfunction; inflammation; reduced anabolic hormone levels.

Short Physical Performance Battery (SPPB)
National Institute on AgingA validated composite physical performance test combining: (1) Balance tests (side-by-side, semi-tandem, tandem stand, 10 seconds each); (2) 4-metre gait speed test; (3) 5-times chair stand test. Total score 0-12 (higher = better). EWGSOP2 threshold: SPPB ≤8 = low physical performance (component of severe sarcopenia). SPPB is also a strong independent predictor of: disability; hospitalisation; institutionalisation; mortality in community-dwelling older adults. Used as an outcome measure in sarcopenia/frailty clinical trials.

Polypharmacy and frailty
WHO/GeriatricsPolypharmacy (typically defined as ≥5 regular medications) is both a cause and consequence of frailty. Adverse drug reactions and drug-drug interactions increase dramatically with age (pharmacokinetic changes — reduced hepatic CYP450, reduced renal clearance) and frailty. Medications that exacerbate frailty: sedatives/hypnotics (falls, delirium); anticholinergics (cognitive impairment, urinary retention, constipation, falls — the Anticholinergic Cognitive Burden scale); antihypertensives (orthostatic hypotension → falls); diuretics (dehydration); opioids (sedation, constipation). Medication review and structured deprescribing (STOPP/START criteria) is a core component of comprehensive geriatric assessment.

Falls and frailty
WHO/Falls preventionFalls are the most common and impactful consequence of frailty and sarcopenia: approximately 30% of community-dwelling adults over 65 fall each year; approximately 50% over 80. Consequences: hip fracture (20-30% mortality at 1 year; 50% never return to prior function); head injury; fear of falling (itself causing activity restriction and further deconditioning — the "fall-frailty spiral"). WHO evidence-based falls prevention: resistance + balance exercises (Otago programme — reduces falls 35-40%); medication review (stop falls-risk medications); vision correction; home hazard modification; vitamin D correction (reduces falls risk in deficient individuals).